EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study

Fumihiko Urabe iD, Yu Imai, Yuma Goto, Kojiro Tashiro, Masaki Hashimoto, Kentaro Yoshihara, Shutaro Yamamoto, Shuhei Hara, Keiichiro Miyajima iD, Wataru Fukuokaya, Yuki Enei, Kosuke Iwatani und 12 weitere

Japanese Journal of Clinical Oncology · 2024

DOI: 10.1093/jjco/hyae098 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Fumihiko Urabe und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Docetaxel, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Two randomized trials demonstrated that the survival benefits afforded by triplet therapy were greater than those of doublet therapy, thus changing the treatment paradigm for metastatic castration-sensitive prostate cancer (mCSPC). This is the first study to assess the real-world use, performance, and safety of triplet therapy in Japanese patients.

Methods

This retrospective multicenter study included 45 consecutive mCSPC patients who received triplet therapy composed of androgen deprivation therapy (ADT), docetaxel, and darolutamide between January 2023 and June 2024. Baseline patient characteristics and their clinical parameters during triplet therapy were collected. Adverse events (AEs) were graded using Common Terminology Criteria for Adverse Events version 5.0, and imaging responses were evaluated following the RECIST criteria. The prostate-specific antigen (PSA) nadir was defined as the lowest PSA value during follow-up, and the PSA decrease was the initial PSA value minus the PSA nadir.

Results

The median patient age was 70 years and the median follow-up duration was 10 months. High-volume disease was present in 82.2% of patients. Concurrent administration of docetaxel and darolutamide was scheduled for 22.2% of cases. The incidence of any AE was 86.7%, with 55.5% of patients experiencing grade 3–4 AEs. Neutropenia was common, but prophylactic granulocyte colony-stimulating factor (G-CSF) significantly reduced the incidence of neutropenia of grade 3 or higher. Febrile neutropenia occurred in four patients (8.9%); these patients had not received prophylactic G-CSF. A decline in PSA of 90% was observed in 95.6% of patients, and an imaging response was seen in 97.8%.

Conclusions

Triplet therapy with ADT, darolutamide, and docetaxel was highly efficacious and tolerable in Japanese mCSPC patients, particularly those with high-volume disease. Prophylactic G-CSF prescription is crucial to manage neutropenia effectively. Further studies with longer follow-ups are needed to confirm these findings and explore the long-term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAgedRetrospective StudiesJapanMiddle AgedAged, 80 and overAndrogen AntagonistsProstatic Neoplasms, Castration-ResistantPyrazolesProstate-Specific AntigenNeoplasm MetastasisEast Asian People

Stichwörter der Autor:innen

adverse eventdarolutamidemetastatic castration-sensitive prostate cancertriplet therapy

Substanzen

DocetaxeldarolutamideAndrogen AntagonistsPyrazolesProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, Jikei University the 3rd Hospital, Tokyo, Japan.
  • Department of Urology, Fuji City General Hospital, Shizuoka, Japan.
  • Department of Urology, Atsugi City Hospital, Atsugi, Japan.
  • Department of Urology, Jikei University Katsushika Medical Cener, Tokyo, Japan.
  • Department of Urology, Ota Memorial Hospital, Ota, Japan.

ORCID-Profile: Fumihiko Urabe, Keiichiro Miyajima, Shunsuke Tsuzuki, Tatsuya Shimomura

Zitieren

APA

Urabe, F., Imai, Y., Goto, Y., Tashiro, K., Hashimoto, M., Yoshihara, K., Yamamoto, S., Hara, S., Miyajima, K., Fukuokaya, W., Enei, Y., Iwatani, K., Kayano, S., Igarashi, T., Aikawa, K., Yanagisawa, T., Kimura, S., Tsuzuki, S., Murakami, M., …, & Kimura, T. (2024). Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae098

Vancouver

Urabe F, Imai Y, Goto Y, Tashiro K, Hashimoto M, Yoshihara K, et al. Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study. Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae098

BibTeX
@article{Urabe2024,
  author = {Urabe, Fumihiko and Imai, Yu and Goto, Yuma and Tashiro, Kojiro and Hashimoto, Masaki and Yoshihara, Kentaro and Yamamoto, Shutaro and Hara, Shuhei and Miyajima, Keiichiro and Fukuokaya, Wataru and Enei, Yuki and Iwatani, Kosuke and Kayano, Sotaro and Igarashi, Taro and Aikawa, Koichi and Yanagisawa, Takafumi and Kimura, Shoji and Tsuzuki, Shunsuke and Murakami, Masaya and Hata, Kenichi and Shimomura, Tatsuya and Yamada, Hiroki and Miki, Jun and Kimura, Takahiro},
  title = {Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1093/jjco/hyae098}
}
Kostenlos starten →